Alkermes plc (ALKS), which delivered a strong quarter marked by solid financial and commercial execution early this month, touched a new high of $38.46 yesterday. With the successful completion of the Avadel acquisition, a strengthened financial profile, and an accelerated entry into the commercial sleep medicine market at scale, the company sees a transformative growth opportunity ahead.
This commercial stage company is focused on developing medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders, including addiction, serious mental illness and sleep disorders. Its portfolio of commercial products includes approved medicines like:
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.